Sulforaphane sensitizes human breast cancer cells to paclitaxel-induced apoptosis by downregulating the NF-κB signaling pathway

SEUNG-HYUN KIM, HYUN-JUNG PARK and DONG-OH MOON

Department of Biology Education, Daegu University, Gyeongsan, Gyeongsang 38453, Republic of Korea

Received July 22, 2015; Accepted November 3, 2016

DOI: 10.3892/ol.2017.5950

Abstract. Sulforaphane (SFN), an isothiocyanate present in cruciferous vegetables, has been demonstrated to inhibit the growth of various types of cancer cell. The aim of the present study was to investigate whether SFN sensitizes breast cancer cells to paclitaxel-induced apoptosis and to identify the signal pathway through which SFN mediates apoptosis. Combined treatment of breast cancer cells with SFN and paclitaxel resulted in increased activation of apoptotic signaling pathway members, including caspase-3, -8 and -9, and cytochrome c, compared with treatment with SFN or paclitaxel alone. In addition, treatment with SFN and paclitaxel resulted in downregulation of the nuclear factor kappa B signaling pathway, and reduced protein expression of apoptosis regulator Bcl-2 and phosphorylated AKT serine/threonine kinase. Furthermore, SFN-paclitaxel-induced apoptosis was inhibited by overexpression of Bcl-2. The results of the present study suggest that combined treatment with SFN and paclitaxel is a novel therapeutic strategy for the treatment of breast cancer.

Introduction

Breast cancer is the most prevalent cancer in females worldwide, with an overall lifetime risk of >10% (1). Paclitaxel, isolated from the bark of Taxus brevifolia, is a potent chemotherapeutic agent used in the treatment of breast cancer (2). Paclitaxel mechanistically interferes with the dynamic instability of microtubules, leading to G2/M cell cycle arrest and subsequent apoptosis (3). However, paclitaxel chemotherapy has had limited success (4) due to the activation of cytoprotective signaling pathways in tumors, including the nuclear factor kappa B (NF-κB), AKT serine/threonine kinase (Akt) and mitogen-activated protein kinase signaling pathways, which induce drug resistance (3-6). In addition, paclitaxel has been implicated in the regulation of NF-κB-dependent genes that promote cell survival and inhibit apoptosis, including apoptosis regulator Bcl-2 and Bcl-2 like 1 (Bcl-xL) (7). Therefore, agents that inhibit paclitaxel-induced NF-κB activation may be effective chemotherapeutic candidates for the treatment of breast cancer.

Sulforaphane (SFN), an isothiocyanate naturally present in cruciferous vegetables, including broccoli, sprouts and kale, has been reported to reduce the risk of developing a number of common types of cancer, including breast cancer (8,9). Previous studies have demonstrated that SFN induces G2/M cell cycle arrest by elevating cyclin B1 expression, and induces apoptosis by activating poly(ADP-ribose) polymerase 1 and caspase family proteins in human breast cancer cell lines (8,10). In addition, SFN was reported to attenuate histone deacetylase activity in prostate epithelial cells (11) and inhibit tubulin polymerization in breast cancer cells (12). Furthermore, SFN has been demonstrated to inhibit NF-κB activation in various diseases, including cancer, skin disorders and spinal cord injury, by inhibiting NF-κB inhibitor alpha (IκBα) phosphorylation, IκBα degradation and p65 nuclear translocation (13). Therefore, SFN may be an effective chemotherapeutic agent.

Building upon previous paclitaxel and SFN research, the present study investigated the effect of combined SFN-paclitaxel treatment on breast cancer cells. The underlying molecular mechanisms of combined SFN and paclitaxel treatment were investigated by evaluating the inhibition of the anti-apoptotic signal transducers Akt and NF-κB. It was observed that treatment with SFN inhibits paclitaxel-induced NF-κB activation, Bcl-2 gene expression and proliferation in breast cancer cells.

Materials and methods

Cell culture. The human breast cancer cell lines MDA-MB-231 and MCF-7 were purchased from the American Type Culture Collection (Manassas, VA, USA). Cells were cultured in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) and antibiotics (100 µg/ml streptomycin and 100 U/ml penicillin; Thermo Fisher Scientific, Inc.), and maintained at 37°C in a humidified atmosphere containing 5% CO₂. Overexpression of Bcl-2 was induced by transfecting...
a PC3.1-Bcl-2 plasmid into MDA-MB-231 cells with Lipofectamine® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.). At 1 day prior to transfection, 1x10⁵ cells in 500 µl of growth medium without antibiotics were seeded in each well of a 24-well plate. When 90-95% confluence was obtained, 0.8 µg of the PC3.1-Bcl-2 plasmid in serum-free 50 µl Opti-MEM I (cat. no. 31985; Invitrogen; Thermo Fisher Scientific, Inc.) was prepared, and 2 µl of Lipofectamine® 2000 was diluted with 50 µl of Opti-MEM I. After waiting 5 min, the diluted Lipofectamine® 2000 was combined with the diluted PC3.1-Bcl-2 plasmid for a total volume of 100 µl, gently mixed, and left to stand for 20 min at room temperature. The 100 µl volume was then added to each well. Following transfection, a stable Bcl-2-overexpressing cell line was generated using neomycin (1000 µg/µl) to select cells. Cells were then maintained at 37°C, in a humidified atmosphere with 5% CO₂.

Reagents. Propidium iodide (PI), MTT, paclitaxel and SFN were obtained from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany). The Caspase 3, 8 and 9 Fluorometric Assay kit was obtained from R&D Systems, Inc. (Minneapolis, MN, USA). The rabbit anti-human primary antibodies anti-Bcl-2 (cat no. MABC573), cytochrome c (cat no. 04-1043), caspase-3 (cat no. AB1899), caspase-8 (cat no. 06-775) and caspase-9 (cat no. AB16969) were purchased from Calbiochem (La Jolla, CA, USA). The rabbit anti-human primary antibodies directed against Akt (cat no. 4691), phosphorylated (P)-Akt (cat no. 4060), IκBα (cat no. 4812), GADPH (cat no. 5174) and P-IκB kinase (P-IKK) (cat no. 2697) were purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA). The primary antibodies were used at a dilution of 1:1,000. All other chemicals not specifically cited here were purchased from Sigma-Aldrich (Merck Millipore).

Cell viability assay. Cells were grown to 70% confluence and treated with increasing concentrations (0-20 µM) of SFN, alone or in combination with 10 nM paclitaxel. Control untreated cells were incubated, with complete media containing 0.1% dimethyl sulfoxide, at 37°C with 5% CO₂ in a humidified atmosphere, for 24 h. Following treatment, cell number and viability was determined using an MTT assay. A volume of 200 µl DMEM containing 2x10⁵ cells was seeded in each well of 48-well plates. Following treatment with SFN and paclitaxel, the plates were incubated for 2 days. For each measurement, 50 µl MTT (5 mg/ml) was added into each well and incubated at 37°C with 5% CO₂ for 2 h. The wells were then decanted, and formed formazan crystals were dissolved in 200 µl DMSO. The absorbance of the plate was measured at 595 nm in an ELISA plate reader. A hemocytometer was additionally used for viable cell counts. All assays were performed in triplicate.

Flow cytometric analysis. Cells were seeded in 6-well plates at a density of 2x10⁵ cells/well and subsequently treated with increasing concentrations (0-20 µM) SFN and paclitaxel alone, or combined, at 37°C for 24 h. Treated and control cells were harvested by trypsinization and stained with PI, according to the manufacturer's protocol. Cell cycle progression was determined using flow cytometry (FACSCalibur™; BD Biosciences, Franklin Lakes, NJ, USA) and data analysis was performed using FlowJo 9.3 software for Mac OS X (Tree Star, Inc., Ashland, OR, USA). To detect apoptosis, cells were harvested and stained using the Annexin-V Apoptosis Detection kit (R&D Systems, Inc.). In brief, the cells were harvested and washed with cold PBS, centrifuged at ~300 x g for 5 to 10 min at room temperature, resuspended in 100 µl of the binding buffer from the kit containing 2.5 µl FITC conjugated Annexin-V and incubated for 15 min at room temperature in the dark. A total of >10,000 events were detected and analyzed by flow cytometry.

Mitochondrial labelling within live cells. SFN-treated cells were stained with 1 µg/ml MitoTracker for 15 min and observed under a fluorescence microscope. Samples were then further analyzed by FACSScan (BD Biosciences). Data analysis was performed using FlowJo 9.3 software (Tree Star, Inc.).

Western blotting. Cells were washed with cold PBS and lysed in a commercial lysis buffer PRO-PREP® (Intron Biotechnology Inc., Seongnam, Korea). Protein concentration was determined using a Bio-Rad Protein Assay kit II (cat. no. 5000002; Bio-Rad Laboratories, Inc., Hercules, CA, USA) according to the manufacturer's protocol. Total protein (30 µg) was separated using 12% SDS-PAGE and transferred to a nitrocellulose membrane (Schleicher & Schuell BioScience, Inc., Keene, NH, USA). The primary antibodies were incubated with the membrane at 4°C overnight. Membranes were then washed and incubated with 5% skimmed milk in tris-buffered saline with Tween 20 for 1 h. Anti-rabbit IgG conjugated to horseradish peroxidase (cat no. 7074; Cell Signaling Technology, Inc.) was used as the secondary antibody. The secondary antibody (dilution, 1:2,000) was incubated at room temperature, for 1 h. Protein bands were visualized using an Amersham Imager 600 enhanced chemiluminescence detection system (GE Healthcare Life Sciences, Chalfont, UK). GADPH was used as a protein loading control.

Preparation of cytosolic extracts. Cells were harvested by gentle scraping and washed in PBS. For preparation of cytosolic extracts, cells were resuspended in ice-cold lysis buffer (250 mM sucrose, 80 mM KCl, 50 µg/ml digitonin, PMSF, and complete™ protease inhibitor in PBS). Following 5 min of incubation on ice the cell suspensions were centrifuged at 10,000 x g for 5 min at-20°C and the supernatants were frozen at -70°C until analysis by western blotting.

Electrophoretic mobility shift assay (EMSA). EMSA was performed on nuclear extracts. Briefly, the preparation of nuclear extracts was conducted using NE-PER nuclear extraction reagents (Pierce; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. Briefly, MDA-MB231 cells treated with SFN and paclitaxel, were harvested using trypsin-EDTA and subsequently washed with PBS. Cytosolic proteins were first extracted by disrupting the cell membranes, followed by centrifugation at 16,000 x g for 5 min at -20°C. Intact nuclei were washed with cold PBS and then lysed with high salt NE-PER buffer. Nuclear fractions were stored at-80°C for use in subsequent experiments. A synthetic complementary NF-κB-binding oligonucleotide (5'-AGT TGA GGG GAC TTT CCC AGG C-3'; Santa Cruz Biotechnology,
Inc., Dallas, TX, USA) was 3'-biotinylated with a Pierce Biotin 3' End DNA Labeling kit used according to the manufacturer's protocol (Thermo Fisher Scientific, Inc.). Binding reactions were conducted with 50 ng/µl poly (dI-dC), 0.05% Nonidet P-40, 5 mM MgCl₂, 10 mM EDTA and 2.5% glycerol in 1X binding buffer (Pierce LightShift™ Chemiluminescent EMSA kit, Thermo Fisher Scientific, Inc.), using 20 fmol of biotin-end-labeled target DNA and 10 µg of nuclear extract, for 20 min at room temperature. Assays were loaded onto native 4% polyacrylamide gels, pre-electrophoresed for 60 min in 0.5X Tris borate in EDTA and electrophoresed at 100 V, followed by transfer onto a positively charged nylon membrane (Hybond™-N⁺; GE Healthcare Life Sciences) in 0.5x Tris borate/EDTA at 100 V for 30 min. Transferred DNAs were cross-linked to the membrane at 120 mJ/cm² and detected using horseradish peroxidase-conjugated streptavidin (from the LightShift™ Chemiluminescent EMSA kit) according to the manufacturer's instructions.

**Statistical analysis.** Values are presented as the mean ± standard deviation of triplicate data. The statistical significance of differences was assessed using a two-way ANOVA followed by Bonferroni's multiple comparison test. GraphPad Software 6 was used for statistical analyses (GraphPad Software Inc., La Jolla, CA, USA). P<0.05 was considered to indicate a statistically significant difference; P<0.01 and P<0.001 were additionally considered as further thresholds of significance.

**Results**

**Combined treatment with SFN and paclitaxel reduces human breast cancer cell viability.** The effect of paclitaxel on cell viability was analyzed in MDA-MB-231 and MCF-7 breast cancer cell lines. Treatment with 10 nM paclitaxel induced limited inhibition of cell viability (<10%) at 24 h, suggesting that these cells are resistant to the apoptotic effects of paclitaxel. The effect of combined treatment with SFN and paclitaxel on cell viability was also examined. Cell viability was significantly decreased by combined treatment with SFN and paclitaxel (MDA-MB231, P=0.001, 0.0001, 0.009, 0.001, respectively; MCF-7, P=0.005, 0.001, 0.004, 0.0002, respectively, for paclitaxel with SFN doses 5, 10, 15 and 20 µM, compared with SFN-only groups; Fig. 1A). The dependence of combined SFN and paclitaxel treatment on apoptosis was subsequently investigated. As shown in Fig. 1B, treatment of MDA-MB2-31 cells with 5 µM SFN and 10 nM paclitaxel for 24 h markedly increased the accumulation of sub-G1 phase.
KIM et al.: SULFORAPHANE POTENTIATES PACLITAXEL-INDUCED APOPTOSIS

These results indicate that combined SFN-paclitaxel treatment increases apoptosis in breast cancer cells.

**SFN inhibits paclitaxel-induced NF-κB activation and IkBα degradation.** The effect of treatment with SFN on paclitaxel-mediated NF-κB activation was evaluated using an EMSA. As shown in Fig. 3A, 10 nM paclitaxel induced an increase in NF-κB binding to complementary oligonucleotides after 15 min, which was sustained for 1 h. Pretreatment with SFN inhibited paclitaxel-induced NF-κB activation in a time-dependent manner (Fig. 3A). To confirm whether paclitaxel-induced NF-κB activation was caused by IKK phosphorylation and IκBα degradation, western blotting of P-IKK and IκBα was performed. As shown in Fig. 3B, IKK phosphorylation and IκBα degradation began 15 min following treatment with paclitaxel, but was markedly decreased following pretreatment with SFN. These results suggest that paclitaxel induces NF-κB activation in MDA-MB-231 cells through the degradation of IκBα and that SFN inhibits IκBα degradation. Since Akt signaling was previously demonstrated to regulate NF-κB activation (5,14), it was evaluated in the present study whether SFN had an effect on cells and Annexin V staining (Fig. 1B). These results indicate that SFN enhances paclitaxel-induced apoptosis and reduces viability in breast cancer cells.

**Combined SFN-paclitaxel treatment activates extrinsic and intrinsic apoptotic pathways.** To confirm the effect of combined treatment with SFN and paclitaxel on apoptosis, caspase-8, -9 and -3 expression and activity was evaluated using western blotting and caspase activity kits, respectively. As shown in Fig. 2A, cleavage of caspase-8, -9 and -3 was observed following treatment with SFN and paclitaxel. By contrast, cleaved caspases were not observed in cells treated with SFN or paclitaxel alone. Furthermore, caspase activity was increased following treatment with SFN and paclitaxel (Fig. 2B). Apoptotic events in the mitochondria were detected by measuring the mitochondrial membrane potential with 3,3′-dihexyloxycarbocyanine iodide dye. A marked reduction in mitochondrial membrane potential was observed in cells following treatment with SFN and paclitaxel (Fig. 2C). In addition, this process was accompanied by the release of cytochrome c from the mitochondria into the cytosol (Fig. 2D).
the phosphorylation of AKT. Pretreatment with SFN abolished paclitaxel-induced Akt phosphorylation (Fig. 3C), indicating that Akt serves a role in the mechanism of action of SFN.

**Bcl-2 overexpression attenuates paclitaxel- and SFN-induced apoptosis.** The level of protein expression of the NF-κB-dependent survival gene Bcl-2 was examined using western blotting. This demonstrated that pretreatment with SFN markedly decreased Bcl-2 protein expression (Fig. 4A), suggesting that SFN-mediated NF-κB inhibition leads to repression of Bcl-2 expression. In addition, overexpression of Bcl-2 notably inhibited paclitaxel/SFN-induced caspase-3 activation (Fig. 4B) and significantly inhibited Annexin V staining (P=0.033, 0.0001, 0.0001, at 24, 48 and 72 h, respectively; Fig. 4C).

Figure 3. SFN inhibits paclitaxel-induced NF-κB activation and IκBα degradation. (A) MDA-MB-231 cells treated with 5 µM SFN and 10 nM paclitaxel were assayed for NF-κB activation using an electrophoretic mobility shift assay. (B) P-IKK and IκBα in cytosolic proteins collected from the assay were detected using a western blot. GAPDH was used as the loading control. (C) Whole cell lysates were resolved on a 10% SDS gel and P-Akt S473 was detected with western blotting. SFN, sulforaphane; NF-κB, nuclear factor kappa B; P, phosphorylated; IκBα, NF-κB inhibitor alpha; Akt, AKT serine/threonine kinase.

Figure 4. Bcl-2 serves a role in SFN/paclitaxel-induced apoptosis. (A) Western blot analysis of Bcl-2 protein expression in MDA-MB-231 cells treated with 5 µM SFN alone, 10 nM paclitaxel alone, or 10 nM paclitaxel and 5 µM SFN for 24 h. (B) MDA-MB-231 cells transfected with Bcl-2 or the vector control were analyzed for activated Cas-3 using western blot analysis. (C) Flow cytometric analysis of positive Annexin V staining. *P<0.05; ***P<0.001. SFN, sulforaphane; Cas, caspase.
Discussion

Paclitaxel, a microtubule stabilizer, is frequently used as a chemotherapeutic agent in the treatment of various types of human carcinoma, including breast cancer (2). However, paclitaxel frequently induces drug resistance (2-5). The present study investigated the synergistic anticancer effect of combined treatment with SFN and paclitaxel in human breast cancer cells. Co-treatment with SFN enhanced paclitaxel-induced apoptosis via increased activation of caspase-3, -8 and -9. Additionally, co-treatment with SFN inhibited paclitaxel-induced NF-κB activation, Bcl-2 expression and Akt phosphorylation in MDA-MB-231 cells. The results of the present study suggest that SFN and paclitaxel exhibit chemopreventive activity by inducing breast cancer cell apoptosis.

NF-κB is a ubiquitously-expressed transcription factor that regulates the expression of various genes associated with cell proliferation, metastasis, cell cycle progression, angiogenesis and apoptosis. Furthermore, the role of NF-κB in chemoresistance is well-established (15,16). Paclitaxel may activate NF-κB through activation of its primary kinase, IKK (2,3). The results of the present study indicate that paclitaxel activates NF-κB in human breast cancer cells through the classic NF-κB activation signaling pathway, IKK activation and IκBα degradation. Treatment of breast cancer cells with SFN suppressed paclitaxel-induced IKK activation, leading to suppression of NF-κB activation.

A previous study (17) demonstrated that paclitaxel activates Akt, a serine/threonine protein kinase, which is a downstream target of phosphoinositide 3-kinase. In the present study, SFN downregulated paclitaxel-induced Akt activation in MDA-MB-231 cells. Similarly, previous studies have shown that treatment with LY294002, a specific inhibitor of phosphoinositide 3-kinase, resulted in enhancement of paclitaxel-induced apoptosis through suppression of NF-κB transcriptional activity (18,19). Several previous studies have shown that NF-κB induces the expression of cyclin D1, Bcl-2 and Bcl-xL (20,21). The results of the present study demonstrated that the protein expression levels of Bcl-2 induced by paclitaxel were decreased following treatment with SFN due to inactivation of NF-κB signaling. Furthermore, Bcl-2 overexpression reversed the effect of combined treatment with SFN and paclitaxel on caspase-3 activity. Therefore, the inhibition of breast cancer cell viability by SFN may be mediated by the inhibition of Bcl-2. In conclusion, SFN enhances the anti-tumorigenic activity of paclitaxel in breast cancer cells by modulating NF-κB activation and Akt inhibition. The results of the present study indicate that combined treatment with paclitaxel and SFN is an effective clinical strategy for the treatment of breast cancer.

Acknowledgements

The present study was supported by a Daegu University 2012 Research Grant (Daegu University, Gyeongsan, Korea).

References